Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Jeffrey W. Clark(Massachusetts General Hospital), Stephen P. Creekmore(Bryan College), Robin Lin Miller(Michigan State University), John W. Smith(SUNY Upstate Medical University), Edward D. Crum, Ronald G. Steis, JoAnn Beman(National Cancer Institute), John Edward McKnight, Henry C. Stevenson(National Cancer Institute), Walter J. Urba(Providence Portland Medical Center)
PubMed
November 15, 1990
Cited by 54
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k